Pfizer and Valneva's Lyme Disease Vaccine MAA Validated by EMA
The European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, a 6-valent outer surface protein A (OspA)-based Lyme disease vaccine candidate developed by Pfizer and Valneva.